Literature DB >> 19058312

Induction of IgA and sustained deficiency of cell proliferative response in chronic hepatitis C.

Yalena Amador-Cañizares1, Liz Alvarez-Lajonchere, Ivis Guerra, Ingrid Rodríguez-Alonso, Gillian Martínez-Donato, Julián Triana, Eddy E González-Horta, Angel Pérez, Santiago Dueñas-Carrera.   

Abstract

AIM: In the present study, antibody and peripheral blood mononuclear cells (PBMC) proliferative responses against hepatitis C virus (HCV) antigens were evaluated in HCV chronically infected patients.
METHODS: Paired serum and PBMC samples were taken six months apart from 34 individuals, either treated or not, and tested by enzyme-linked immunosorbent assay (ELISA) and carboxyfluorescein succinimidyl ester staining.
RESULTS: Over 70% of the patients showed specific IgG and IgM against capsid, E1 and NS3, while HVR-1 was recognized by half of the patients. An increase in the levels of the anti-capsid IgM (P = 0.027) and IgG (P = 0.0006) was observed in six-month samples, compared to baseline. Similarly, a significantly higher percent of patients had detectable IgA reactivity to capsid (P = 0.017) and NS3 (P = 0.005) after six months, compared to baseline. Particularly, IgA against structural antigens positively correlated with hepatic damage (P = 0.036). IgG subclasses evaluation against capsid and NS3 revealed a positive recognition mediated by IgG1 in more than 80% of the individuals. On the contrary, less than 30% of the patients showed a positive proliferative response either of CD4+ or CD8+ T cells, being the capsid poorly recognized.
CONCLUSION: These results confirm that while the cellular immune response is narrow and weak, a broad and vigorous humoral response occurs in HCV chronic infection. The observed correlation between IgA and hepatic damage may have diagnostic significance, although it warrants further confirmation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19058312      PMCID: PMC2773881          DOI: 10.3748/wjg.14.6844

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  45 in total

1.  IgG subclass distribution of hepatitis B surface antigen antibodies induced in children with chronic hepatitis B infection after interferon-alpha therapy.

Authors:  H Gregorek; K Madaliński; M Woynarowski; J Mikolajewicz; M Syczewska; J Socha
Journal:  J Infect Dis       Date:  2000-05-31       Impact factor: 5.226

2.  Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C.

Authors:  N H Grüner; T J Gerlach; M C Jung; H M Diepolder; C A Schirren; W W Schraut; R Hoffmann; R Zachoval; T Santantonio; M Cucchiarini; A Cerny; G R Pape
Journal:  J Infect Dis       Date:  2000-05-05       Impact factor: 5.226

3.  Immunological evaluation of Escherichia coli-derived hepatitis C virus second envelope protein (E2) variants.

Authors:  S Dueñas-Carrera; A Viña; H E Garay; O Reyes; L Alvarez-Lajonchere; I Guerra; L J González; J Morales
Journal:  J Pept Res       Date:  2001-09

4.  [Dendritic cells and hepatitis C virus].

Authors:  C Bain; G Inchauspé
Journal:  Pathol Biol (Paris)       Date:  2001-07

Review 5.  Elevated circulating transforming growth factor beta-1 may explain poorer renal survival in type II diabetics with chronic hepatitis C.

Authors:  Michael C Peterson
Journal:  Med Sci Monit       Date:  2007-05

6.  Functional suppression by FoxP3+CD4+CD25(high) regulatory T cells during acute hepatitis C virus infection.

Authors:  Susan Smyk-Pearson; Lucy Golden-Mason; Jared Klarquist; James R Burton; Ian A Tester; Chia C Wang; Nicole Culbertson; Arthur A Vandenbark; Hugo R Rosen
Journal:  J Infect Dis       Date:  2008-01-01       Impact factor: 5.226

7.  IgM antibody to a hepatitis C virus core peptide (CP14) for monitoring activity of liver disease in patients with acute or chronic hepatitis C.

Authors:  R Nagayama; K Miyake; F Tsuda; H Okamoto
Journal:  J Med Virol       Date:  1994-03       Impact factor: 2.327

Review 8.  Nonresponse to treatment for hepatitis C: current management strategies.

Authors:  He-Jun Yuan; William M Lee
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Humoral immune response in acute hepatitis C virus infection.

Authors:  Dale M Netski; Tim Mosbruger; Erik Depla; Geert Maertens; Stuart C Ray; Robert G Hamilton; Stacy Roundtree; David L Thomas; Jane McKeating; Andrea Cox
Journal:  Clin Infect Dis       Date:  2005-07-22       Impact factor: 9.079

10.  Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C.

Authors:  Jan M Pestka; Mirjam B Zeisel; Edith Bläser; Peter Schürmann; Birke Bartosch; Francois-Loïc Cosset; Arvind H Patel; Helga Meisel; Jens Baumert; Sergei Viazov; Kay Rispeter; Hubert E Blum; Michael Roggendorf; Thomas F Baumert
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-28       Impact factor: 11.205

View more
  2 in total

1.  HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin.

Authors:  Yalena Amador-Cañizares; Gillian Martínez-Donato; Liz Alvarez-Lajonchere; Claudia Vasallo; Mariacarla Dausá; Daylen Aguilar-Noriega; Carmen Valenzuela; Ivette Raíces; Jean Dubuisson; Czeslaw Wychowski; Zurina Cinza-Estévez; Marlén Castellanos; Magdalys Núñez; Anny Armas; Yaimé González; Ismariley Revé; Ivis Guerra; Angel Pérez Aguiar; Santiago Dueñas-Carrera
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

2.  Protective T Cell and Antibody Immune Responses against Hepatitis C Virus Achieved Using a Biopolyester-Bead-Based Vaccine Delivery System.

Authors:  G Martínez-Donato; B Piniella; D Aguilar; S Olivera; A Pérez; Y Castañedo; L Alvarez-Lajonchere; S Dueñas-Carrera; J W Lee; N Burr; M Gonzalez-Miro; B H A Rehm
Journal:  Clin Vaccine Immunol       Date:  2016-04-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.